-
???insights.card.a11y.category??? news News
Obesity drug supply-demand imbalance is working in Novo Nordisk’s favor: Mizuho’s Jared Holz
-
???insights.card.a11y.category??? news News
Mizuho’s Konstam warns of 20%-30% downside for equities
-
???insights.card.a11y.category??? news News
PayPal’s AI announcement is ‘shockingly unshocking’, says Mizuho’s Dan Dolev
-
???insights.card.a11y.category??? news News
Mizuho’s life insurance swaptions notional climbs 575% in a year
-
???insights.card.a11y.category??? news News
Medical device companies ‘clear beneficiary’ following Humana’s warning, says Mizuho’s Jared Holz
-
???insights.card.a11y.category??? news News
Bitcoin ETFs not good for Coinbase: Mizuho's Dolev
-
???insights.card.a11y.category??? news News
Price compression of bitcoin trading begins today, says Mizuho’s Dan Dolev
-
???insights.card.a11y.category??? news News
Eli Lilly’s DTC obesity drug push ‘not necessarily an industry game changer’: Mizuho’s Jared Holz
-
???insights.card.a11y.category??? news News
Mizuho’s Holz on weight loss drugs: Lilly and Novo Nordisk are in excellent shape fundamentally